A cure for range anxiety?
Category: biotech/medical – Page 1,579
Cyborgs in the streets
I don’t know how about you… But I’m meeting cyborgs in the streets regularly. If you observe carefully you can find people with artificial legs and arms. So next time watch more carefully. Its most common seen artificial body part. On other hand there are other parts you can’t see, like artificial joints, dental implants, breast implants, pacemakers, insulin pumps and so on. We are unable to see them but they are very common. Millions people use them. Nowadays very common trend is biohacking where people implant magnets and chips to their bodies. We think our bodies are born complete but we are wrong. We can upgrade and modify them. What if we can use brain implants to be smarter, to think and focus sharper.
Link: Big Pharma loses top scientist to anti-aging research
https://www.google.com/amp/s/amp.ft.com/content/2b869472-…28788e8dd4
“GlaxoSmithKline’s chief scientific officer Hal Barron will step down in August as he moves to lead a Silicon Valley anti-ageing start-up, dealing a blow to the pharma group as it races to rebuild its pipeline of drugs.”
GSK loses top scientist to anti-ageing start-up
Link: Big Pharma loses top scientist to anti-aging research.
GlaxoSmithKline’s chief scientific officer Hal Barron will step down in August as he moves to lead a Silicon Valley anti-ageing start-up, dealing a blow to the pharma group as it races to rebuild its pipeline of drugs.
Hal Barron, a veteran drug developer, helped shape GSK efforts when some shareholders raised concerns that chief executive Emma Walmsley’s lack of a scientific background was a hindrance. He will be replaced by internal candidate Tony Wood.
Barron is leaving GSK to take up the top job at Altos Labs, a start-up reportedly backed by billionaires including Amazon founder Jeff Bezos. He will remain on GSK’s board as a non-executive director and continue to provide scientific advice.
New Virus-Like Particles Can Deliver CRISPR to Any Cell in the Body
One critical difference? Unlike a Mars mission’s “seven minutes of terror,” during which the entry, descent, and landing occur too fast for human operators to interfere, gene therapy delivery is completely blind. Once inside the body, the entire flight sequence rests solely on the design of the carrier “spaceship.”
In other words, for gene therapy to work efficiently, smarter carriers are imperative.
This month, a team at Harvard led by Dr. David Liu launched a new generation of molecular carriers inspired by viruses. Dubbed engineered virus-like particles (eVLPs), these bubble-like carriers can deliver CRISPR and base editing components to a myriad of organs with minimal side effects.
Google’s $1.5 billion research center to “solve death”
Google has been developing what is perhaps the company’s most ambitious project to date: a science startup that will pursue ‘solutions for aging’ with the intended goal of “solving death”.
Calico, a company directed by futurists to explore the concept of “singularity”, has partnered with pharmaceutical giants to research and trial new market drugs that target aging and development.
What is this new audacious project? Who is behind it? In the following feature, Ethan Nash explores.
To Elon Musk, on the Future of Our Brains
By: alfonso fasano & benjamin stecher.
The following was written out of a shared belief that there are only two things that can change the world. A big army and a big idea. This is a distillation of our big idea.
Dear Elon Musk.
We are writing out of concern. Concern for ourselves, our patients, and the tens of millions of minds around the world you reach. You see, we have a problem. Patients and physicians in the neuromodulation community consistently misinterpret your public comments. It is very important to us that we do not overinflate expectations or unnecessarily hype these products beyond what is possible.
Commentary: To avoid the superbug pandemic, we must fix the antibiotics business
Doctors must be careful when they consider treating their patients with the newest antibiotics, because every time these drugs are used, bacteria have a chance to build resistance. As a result, new antibiotics are generally used sparingly–leaving antibiotic companies with little chance of selling enough doses to recoup their investment.
If scientists don’t discover new antibiotics soon, the world will eventually return to the pre-antibiotic era when simple cuts could kill.
Delivery robots get airbags to protect you in case of collision
Autonomous vehicle maker Nuro has added external airbags to its self-driving delivery robots to protect pedestrians — but there’s reason to be skeptical about their effectiveness.
Drivers wanted: During the pandemic, more people started ordering their food, groceries, and other goods for delivery rather than venturing into stores and restaurants for them.
This has led to an increased demand for delivery drivers that companies have had trouble meeting.
